tradmap

INKT Financials MiNK Therapeutics, Inc.

6 years of revenue, profit, cash flow and balance-sheet history through FY2025, from SEC filings — with a computed, factual read of the trend. Updated Overview →

Financial health

  • Operating income covered interest expense 115× in the latest year, up from -6.0× 5 years ago.
Revenue & net income
-$30M -$15M $0 2020 2021 2022 2023 2024 2025
RevenueNet income
Margins (gross / operating / net)
0% 50% 100% 2020 2021 2022 2023 2024 2025
GrossOperatingNet
Free cash flow (CFO − capex)
-$19M -$10M $0 2020 2021 2022 2023 2024 2025
Free cash flow
Cash vs total debt
$0 $19M $39M 2020 2021 2022 2023 2024 2025
CashTotal debt
Cash flow: operating / investing / financing
-$19M $15M $49M $0 2020 2021 2022 2023 2024 2025
OperatingInvestingFinancing

Key annual figures

FYRevenueNet incomeGross MOp MFCFTotal debtCash
2025 -$12M $13M
2024 -$11M $5M
2023 -$22M -$16M $3M
2022 -$28M -$19M $20M
2021 -$30M -$13M $39M
2020 -$16M -$8M

Frequently asked questions

Is INKT growing its revenue and profit?

See the revenue and net-income charts above for MiNK Therapeutics, Inc.'s multi-year trend.

How much debt does INKT have?

As of FY2025, MiNK Therapeutics, Inc. reported — of total debt against $13M of cash; operating income covered interest expense 115×.

What is INKT's profit margin?

In FY2025, gross margin was —, operating margin —, and net margin —.

Where does this data come from?

All figures are extracted from the company’s SEC EDGAR/XBRL filings — 10-K annual reports and 10-Q quarterly reports (use the Annual / Quarterly toggle). Quarterly figures are derived from the as-filed statements (year-to-date amounts are differenced into discrete quarters). Growth rates and ratios are computed by tradmap; nothing here is investment advice.

Source: SEC EDGAR / XBRL (10-K + 10-Q filings) · prices EOD (Databento), corporate-action-adjusted · growth rates, valuation multiples & ratios computed by tradmap. Valuation uses each month-end price against the latest annual filing. Informational only — not investment advice.